TRANSITION THERAPEUTICS INC. T.TTH

AGM WebCast.................

[deninsask]

This years AGM Webcast..... Dec 11, 2006 Transition Therapeutics to Webcast Annual and Special Meeting of Shareholders TORONTO, ON, December 11th, 2006 - Transition Therapeutics Inc. ("Transition") (TSX: TTH), announced that its Annual and Special Meeting of Shareholders occurring today will be webcast live and can be accessed by visiting Transition's website at https://www.transitiontherapeutics.com. The Annual and Special Meeting of Shareholders will take place at the MaRS Discovery District, MaRS Centre, South Tower, 101 College Street, Ground Floor, Rm CR3, Toronto, Ontario, today at 4:30 p.m. EST. The meeting will include an overview of Transition and its key programs provided by Dr. Tony Cruz, Chairman and Chief Executive Officer of Transition. A replay will be available on the Transition website. About Transition Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. Transition's lead products include regenerative therapies E1-I.N.T.™ and GLP1-I.N.T.™ for the treatment of diabetes, AZD-103 for the treatment of Alzheimer's disease, and HCV-I.E.T. for the treatment of hepatitis C. Transition has an emerging pipeline of preclinical drug candidates developed using its proprietary drug discovery engine. Transition's shares are listed on the Toronto Stock Exchange under the symbol "TTH". For additional information about the company, please visit www.transitiontherapeutics.com. Notice to Readers: Information contained in our press releases should be considered accurate only as of the date of the release and may be superseded by more recent information we have disclosed in later press releases, filings with the OSC or otherwise. Press releases may contain forward-looking statements based on the expectations of our management as of the date of the release. Actual results may materially differ based on many factors, including those described in the press releases. For further information on Transition, visit www.transitiontherapeutics.com or contact: Dr. Tony Cruz Chief Executive Officer Transition Therapeutics Inc. Phone: [phone], x.223 [e-mail]; Mr. Elie Farah CFO and VP, Corporate Development Transition Therapeutics Inc. Phone: [phone], x.203 [e-mail]